Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

Cited In for PubMed (Select 15057881)

1.

Beliefs about weight and breast cancer: an interview study with high risk women following a 12 month weight loss intervention.

Wright CE, Harvie M, Howell A, Evans DG, Hulbert-Williams N, Donnelly LS.

Hered Cancer Clin Pract. 2015 Jan 9;13(1):1. doi: 10.1186/s13053-014-0023-9. eCollection 2015.

2.

The construct of breast cancer risk perception: need for a better risk communication?

de Jonge ET, Vlasselaer J, Van de Putte G, Schobbens JC.

Facts Views Vis Obgyn. 2009;1(2):122-9. Review.

3.

Risk determination and prevention of breast cancer.

Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, Gescher AJ, Key TJ, Saxton JM, Harvie MN.

Breast Cancer Res. 2014 Sep 28;16(5):446. doi: 10.1186/s13058-014-0446-2.

4.

Preventive treatments for breast cancer: recent developments.

Alés-Martínez JE, Ruiz A, Chacón JI, Lluch Hernández A, Ramos M, Córdoba O, Aguirre E, Barnadas A, Jara C, González S, Plazaola A, Florián J, Andrés R, Sánchez Rovira P, Frau A.

Clin Transl Oncol. 2015 Apr;17(4):257-63. doi: 10.1007/s12094-014-1250-2. Epub 2014 Dec 2.

5.

Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I.

Warwick J, Birke H, Stone J, Warren RM, Pinney E, Brentnall AR, Duffy SW, Howell A, Cuzick J.

Breast Cancer Res. 2014 Oct 8;16(5):451. doi: 10.1186/s13058-014-0451-5.

6.

Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?

Prosperi MC, Ingham SL, Howell A, Lalloo F, Buchan IE, Evans DG.

BMC Med Inform Decis Mak. 2014 Oct 1;14:87. doi: 10.1186/1472-6947-14-87.

7.

Breast Cancer Risk - Genes, Environment and Clinics.

Fasching PA, Ekici AB, Adamietz BR, Wachter DL, Hein A, Bayer CM, Häberle L, Loehberg CR, Jud SM, Heusinger K, Rübner M, Rauh C, Bani MR, Lux MP, Schulz-Wendtland R, Hartmann A, Beckmann MW.

Geburtshilfe Frauenheilkd. 2011 Dec;71(12):1056-1066.

8.

Pathogenesis, prevention, diagnosis and treatment of breast cancer.

Shah R, Rosso K, Nathanson SD.

World J Clin Oncol. 2014 Aug 10;5(3):283-98. doi: 10.5306/wjco.v5.i3.283. Review.

9.

Current strategies for the prevention of breast cancer.

Advani P, Moreno-Aspitia A.

Breast Cancer (Dove Med Press). 2014 May 2;6:59-71. doi: 10.2147/BCTT.S39114. eCollection 2014. Review.

10.

Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis.

Fasching PA, Ekici AB, Wachter DL, Hein A, Bayer CM, Häberle L, Loehberg CR, Schneider M, Jud SM, Heusinger K, Rübner M, Rauh C, Bani MR, Lux MP, Schulz-Wendtland R, Hartmann A, Beckmann MW.

Geburtshilfe Frauenheilkd. 2013 Dec;73(12):1228-1235.

11.

Assessing the goodness of fit of personal risk models.

Gong G, Quante AS, Terry MB, Whittemore AS.

Stat Med. 2014 Aug 15;33(18):3179-90. doi: 10.1002/sim.6176. Epub 2014 Apr 22.

12.

Immune cell quantitation in normal breast tissue lobules with and without lobulitis.

Degnim AC, Brahmbhatt RD, Radisky DC, Hoskin TL, Stallings-Mann M, Laudenschlager M, Mansfield A, Frost MH, Murphy L, Knutson K, Visscher DW.

Breast Cancer Res Treat. 2014 Apr;144(3):539-49. doi: 10.1007/s10549-014-2896-8. Epub 2014 Mar 5.

13.

Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK.

Brentnall AR, Evans DG, Cuzick J.

Br J Cancer. 2014 Feb 4;110(3):827-8. doi: 10.1038/bjc.2013.747. Epub 2014 Jan 21. No abstract available.

14.

Association between PARP-1 V762A polymorphism and breast cancer susceptibility in Saudi population.

Alanazi M, Pathan AA, Abduljaleel Z, Shaik JP, Alabdulkarim HA, Semlali A, Bazzi MD, Parine NR.

PLoS One. 2013 Dec 31;8(12):e85541. doi: 10.1371/journal.pone.0085541. eCollection 2013. Erratum in: PLoS One. 2014;9(3):e92360. Arifeen, Zainul [corrected to Abduljaleel, Zainularifeen].

15.

An assessment of existing models for individualized breast cancer risk estimation in a screening program in Spain.

Arrospide A, Forné C, Rué M, Torà N, Mar J, Baré M.

BMC Cancer. 2013 Dec 10;13:587. doi: 10.1186/1471-2407-13-587.

16.

Assessment of the clinical utility of the Gail model in estimating the risk of breast cancer in women from the Indian population.

Challa VR, Swamyvelu K, Shetty N.

Ecancermedicalscience. 2013 Oct 17;7:363. doi: 10.3332/ecancer.2013.363. eCollection 2013.

17.

Hereditary cancer risk assessment: essential tools for a better approach.

Gomy I, Estevez Diz Mdel P.

Hered Cancer Clin Pract. 2013 Oct 28;11(1):16. doi: 10.1186/1897-4287-11-16.

18.

Validation of Rosner-Colditz breast cancer incidence model using an independent data set, the California Teachers Study.

Rosner BA, Colditz GA, Hankinson SE, Sullivan-Halley J, Lacey JV Jr, Bernstein L.

Breast Cancer Res Treat. 2013 Nov;142(1):187-202. doi: 10.1007/s10549-013-2719-3. Epub 2013 Oct 26.

19.

Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention.

Reimers L, Crew KD.

Curr Breast Cancer Rep. 2012 Sep 1;4(3):207-215.

20.

Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre.

MacInnis RJ, Bickerstaffe A, Apicella C, Dite GS, Dowty JG, Aujard K, Phillips KA, Weideman P, Lee A, Terry MB, Giles GG, Southey MC, Antoniou AC, Hopper JL.

Br J Cancer. 2013 Sep 3;109(5):1296-301. doi: 10.1038/bjc.2013.382. Epub 2013 Aug 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk